Pictured: Dr. Hanh Nguyen (Research Officer), Dr. Khashayar Farrokzhad (Senior Research Officer) and Mr. Bill Hopper (Technical Director)
ZiP Diagnostics made its first conference appearance at the recent AusMedtech 2022.
AusMedtech was a two-day conference (25-26 May) which showcased Australia's flourishing medtech network. There were over 450 Australian and international delegates present to discuss this year's theme of "Medtech and Manufacturing".
​
There was significant interest at the ZiP Diagnostics' booth, with delegates keen to see an Australian-made molecular point-of-care test platform. All main components of the test have been designed, developed and manufactured in Melbourne. ZiP's PC2 laboratory and manufacturing clean rooms are based in Collingwood.
​
The ZiP-CoVx-P2* test provides a point-of-care result for SARS-CoV-2 within 30 minutes. Clinical trials are currently underway and aims to have performance equivalent to lab-based PCR. Regulatory submissions to Australia's TGA and Europe's IVDR are in preparation.
*The ZiP-CoVx-P2 test is not approved for use in all markets.